Drug policy 101: Pharmaceutical marketing tactics

  • February 4, 2020

Pharmaceutical marketing aims to shape both patient and clinician perceptions about a drug’s benefit and can significantly impact patient and clinician decisions that then affect outcomes, in addition to draining government and health care system resources.

When the best prescription is deprescribing

  • January 29, 2020

Maisha Draves, MD, Medical Director for Pharmacy in Northern California, The Permanente Medical Group Lynn Deguzman, PharmD, Regional Clinical Operations Manager, Kaiser Permanente Northern California Several years ago, an elderly patient — let’s call her Eve — came to Kaiser…

Rena Conti

Determining drug value: Let’s start with the evidence

  • October 24, 2019

Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…

Drug policy 101: Breaking down different types of drug products

  • October 22, 2019

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions.

Drug policy 101: The state of the pharmaceutical evidence base

  • September 26, 2019

Having sound evidence about a drug’s safety and effectiveness is critical to understanding its benefits and value. In recent years, shifts in the pharmaceutical evidence base have created challenges for evaluating drugs after they come to market.

Drug policy 101: Biosimilars

  • January 1, 2019

Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending.